EVENT NEWS ARTICLE
May 16, 2013
Gambro at the 50th ERA-EDTA Congress in Istanbul – Turkey
Meet up with Gambro at the ERA-EDTA, May 18-21, this year’s highlights will include;
Evodial – a unique layer of care
Evodial ® is the first and only dialyzer with a heparin-grafted membrane. Clinical trials* have
shown that Evodial supports individualization of anticoagulant treatment by allowing
significant reductions of the systemic heparin dose, without compromising the dialysis
session. The Evodial dialyzer can reduce patient and healthcare professional concerns
associated with the risk of bleeding.
*Heparin-grafted dialysis membrane allows minimal systemic a nticoagulation in regular hemodialysis patients: A
prospective proof-of-concept study. Published in Hemodialysis International: Volume 17, Issue 2, April 2013.
Hemocontrol™ therapy – adapting therapies to every individual
Hemocontrol is a biofeedback system for individualized, physiological sodium-water
management. Throughout each session, you can ensure the optimal water removal as the
same time as the hydration status is normalized. Let us discuss at the ERA-EDTA how you
easily can program Hemocontrol with the advanced yet simple dialysis system Artis™.
SelectBag® Citrate – a dialysis fluid containing citrate for patient well-being
Ensuring quality of life for hemodialysis patients is one of the goals of the SelectBag® Citrate
concentrate from Gambro —the citrate-containing, acetate-free dialysis fluid for regular
hemodialysis and hemodiafiltration treatment. Citrate is a well-known antioxidant and
anticoagulant and the SelectBag Citrate concentrate aims to reduce stress during treatment
and improve dialysis efficiency. Citrate is a natural metabolite providing both energy and
buffering capacity to patients.
The Hygienic Chain – a holistic approach to optimizing dialysis fluid purity
Maintaining fluid purity means attending to the entire chain of components and processes
involved in HD, from water treatment and concentrates to fluid distribution and HD machines.
At Gambro we call it The Hygienic Chain. And like any chain, it is only as strong as its
weakest link. This has never been truer than in the prevention of biofilm. That is why Gambro
has designed an entire HD system to ensure optimal care while protecting patients from the
hazards of biofilm every step of the way.
Gambro is the world leader in continuous renal replacement therapy (CRRT)
We invite you to stop by our booth and learn more about FleXitrate - full citrate-calcium
CRRT- lets you choose the best possible protocol for your patients’ needs.
Lunch symposium - “Is there a need for more permeable dialysis membranes in
ESRD”. May 19 at 12.30-14.15 Room: EMIGRAN (level B2)
Chairperson: Prof. Claudio Ronco, Vicenza, Italy
Speakers:
Dr. Richard Ward, Louisville, USA
Dr. Paul Cockwell, Birmingham, UK
Dr. Ugo Teatini, Bollate-Milan, Italy
The symposium will look at how current dialysis strategies meet the need to remove a wide
molecular size range of uremic retention solutes.
Let us share our experience and knowledge with you and discuss further.
Please visit our booth at the Istanbul Congress Center, B5 level, booth no.N3
For more information about Gambro at the ERA-EDTA please read here
(Will be linked to http://www.gambro.com/en/global/Other/EDTA-2013/)
or contact:
Gambro media relations
Phone: +46 733 16 97 94
Gambro.communications@gambro.com
About Gambro
Gambro is a global medical technology company and a leader in developing, manufacturing
and supplying products and therapies for Kidney and Liver dialysis, Myeloma Kidney
Therapy, and other extracorporeal therapies for Chronic and Acute patients. Gambro was
founded in 1964 and has today 7 500 employees, 13 production facilities in 9 countries, and
sales in more than 90 countries.
www.gambro.com
Follow us on twitter http://twitter.com/#!/gambrocorporate